New York, New York, USA, November 5, 2026
Elysium Health, Inc. has announced plans to expand its peptide portfolio by offering six additional peptide compounds through its physician-supervised healthcare platform, Elysium Health Rx, following a new interim enforcement-discretion policy issued by the U.S. Department of Health and Human Services (HHS). The announcement represents a significant development in the company’s longevity science and research strategy, combining expanded access to peptide-based products with initiatives designed to strengthen scientific evidence and product quality. The six peptides covered by the policy are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Elysium expects these compounds to become available through its healthcare platform by the end of 2026, subject to applicable regulations and individual medical evaluation by independent board-certified physicians. Alongside the expanded peptide offering, the company announced two research initiatives: the Elysium Peptide Evidence and Evaluation Resource (PEER) and TIME-PEP, a planned study examining epigenetic changes associated with peptide use and their potential relationship with biological aging. The initiatives aim to address the gap between increasing consumer interest in peptide-based interventions and the limited human clinical evidence currently available. Elysium stated that its approach will emphasize scientific evaluation, controlled supply chains, quality characterization and medically supervised access.
PEER Program Aims to Strengthen Peptide Research
A major component of the announcement is the launch of the Peptide Evidence and Evaluation Resource (PEER), an institutional research program designed to support scientific investigations into the safety, mechanisms and potential clinical applications of selected peptides. Through PEER, Elysium plans to provide qualified universities, hospitals, nonprofit organizations and other research institutions with access to high-purity, rigorously characterized peptide materials through a controlled and traceable supply chain. The program will bring together scientists, clinicians and specialized experts to identify research priorities and encourage systematic evaluation of peptide compounds. Its primary objective is to support the generation of reliable scientific information, particularly in areas where human clinical evidence remains insufficient. Research activities are expected to examine peptide characteristics, biological mechanisms, safety considerations and possible therapeutic applications. The company believes that improving access to well-characterized research materials can help investigators conduct more consistent and reproducible studies. PEER is intended to strengthen the scientific foundation of peptide research rather than establish the clinical effectiveness of the compounds. The initiative also reflects the growing importance of quality standards, manufacturing transparency and scientific oversight in the expanding longevity and peptide research sectors.
TIME-PEP Study to Investigate Biological Aging
Elysium also announced plans to initiate TIME-PEP, an expert-led research study through its Aging Research Center (ARC). The planned investigation will examine epigenetic patterns and changes associated with peptide use, including potential relationships with biological age, morbidity and mortality. Epigenetics refers to biological processes that influence how genes are expressed without changing the underlying DNA sequence. Researchers increasingly investigate epigenetic markers to understand aging processes and identify measurable changes associated with health and disease. TIME-PEP aims to collect and evaluate relevant data from peptide users, potentially enabling researchers to investigate associations between peptide exposure and biological aging indicators over time. The initiative builds on the company’s previous TIME-A research model, which focuses on studying aging-related biological measurements. Through its digitally enabled research platform, ARC aims to facilitate consumer participation in longevity research and contribute to a broader epigenetic dataset. However, epigenetic changes or biological-age measurements do not independently establish improved health, longer lifespan or reduced disease risk. Further controlled clinical investigations will be required to determine whether any observed associations represent meaningful health benefits. The planned study is expected to contribute additional information to the developing scientific understanding of peptide use and human aging.
Advertisement
HHS Policy Introduces Conditional Peptide Compounding Access
The company’s announcement follows an interim enforcement-discretion policy issued by HHS on October 28, 2026, concerning the compounding of six specified peptide bulk drug substances under Section 503A of the Federal Food, Drug, and Cosmetic Act. The policy allows certain state-licensed pharmacies, federal facilities and licensed physicians to compound products containing these peptides under specified conditions while the regulatory process continues. Requirements include appropriate ingredient characterization, manufacturing and quality safeguards, patient-specific prescriptions and adverse-event reporting. Importantly, the HHS policy does not constitute FDA approval of these peptides, and compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before marketing. Human clinical evidence supporting these compounds remains limited. Elysium stated that it intends to apply its quality and scientific standards to its expanded peptide program while providing access through independent medical professionals. The company also plans to involve specialized scientific advisors in evaluating emerging evidence and guiding future research priorities. Overall, the announcement represents an important expansion of Elysium Health’s longevity science strategy, combining peptide access with institutional research and investigations into biological aging. The success of these initiatives will depend on rigorous clinical evidence, product quality and continued regulatory oversight.
Source: Elysium Health press release
